首页> 美国卫生研究院文献>BMJ Open Access >Original article: Daclatasvir plus sofosbuvir with or without ribavirin achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

【2h】

Original article: Daclatasvir plus sofosbuvir with or without ribavirin achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

机译：原始文章：达卡他韦加索非布韦有或没有利巴韦林在现实世界中的HCV感染和晚期肝病患者中均获得了较高的持续病毒学应答率

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

ObjectiveWe assessed the effectiveness and safety of daclatasvir (DCV) plus sofosbuvir (SOF), with or without ribavirin (RBV), in a large real-world cohort, including patients with advanced liver disease.

机译：目的我们评估了在大型现实世界中包括晚期肝病患者的达卡他韦（DCV）联合索非布韦（SOF）联合或不联合利巴韦林（RBV）的有效性和安全性。

著录项

期刊名称 BMJ Open Access
作者
Tania M Welzel; Jörg Petersen; Kerstin Herzer; Peter Ferenci; Michael Gschwantler; Heiner Wedemeyer; Thomas Berg; Ulrich Spengler; Ola Weiland; Marc van der Valk; Jürgen Rockstroh; Markus Peck-Radosavljevic; Yue Zhao; Maria Jesus Jimenez-Exposito; Stefan Zeuzem;
展开▼
作者单位

展开▼
年(卷),期 -1(65),11
年度 -1
页码 1861–1870
总页数 10
原文格式 PDF
正文语种
中图分类
关键词
ANTIVIRAL THERAPY CHRONIC VIRAL HEPATITIS CIRRHOSIS HEPATITIS C;

机译：抗病毒治疗;慢性病毒性肝炎;肝硬化;丙型肝炎;

相似文献

外文文献
中文文献
专利

1. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort [J] . Welzel Tania M., Petersen Joerg, Herzer Kerstin, Gut: Journal of the British Society of Gastroenterology . 2016,第11期

机译：达卡他韦加索非布韦联合利巴韦林或不联合利巴韦林，在现实世界中的丙型肝炎病毒感染和晚期肝病患者中均实现了较高的持续病毒学应答率
2. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort (vol 65, pg 1861, 2016) [J] . Welzel T. M., Petersen J., Herzer K. Gut: Journal of the British Society of Gastroenterology . 2016,第12期

机译：达卡他韦加索非布韦联合利巴韦林或不联合利巴韦林在现实队列中对HCV感染和晚期肝病患者实现了较高的持续病毒学应答率（第65卷，第1861页，2016年）
3. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort [J] . Welzel Tania M., Petersen Joerg, Herzer Kerstin, Gut: Journal of the British Society of Gastroenterology . 2016,第11期

机译：daclatasvir加上Sofosbuvir，有或没有利巴韦林，在真实世界的队列中患有HCV感染和晚期肝病患者的高持续病毒学应答率
4. Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life [C] . D.T. Dieterich, M. Rodriguez Torres, J.K. Rockstroh International AIDS Conference . 2004

机译：HCV / HIV的患者在用Peginterferon Alfa-2a（Pegasys）加上利巴韦林（Copegegs）后HCV治疗后实现持续的病毒学反应，具有改善的健康相关的生活质量
5. Baseline Toronto HCC Risk Index (THRI) and Albumin Predict Low Risk of Hepatocellular Carcinoma (HCC) after Sustained Virological Response (SVR) in HCV Infection [D] . Lau, Jason. 2019

机译：基线多伦多HCC风险指数（THRI）和白蛋白预测HCV感染持续病毒响应（SVR）后肝细胞癌（HCC）的低风险
6. Erratum: Daclatasvir plus sofosbuvir with or without ribavirin achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort [O] . -1

机译：勘误：在真实队列中HCV感染和晚期肝病患者在有或没有利巴韦林的情况下达卡他韦加索非布韦均具有较高的持续病毒学应答率
7. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort [O] . Welzel, Tania Mara, Petersen, Jörg, Herzer, Kerstin, 2016

机译：达卡他韦加索非布韦联合利巴韦林或不联合利巴韦林，在现实世界中的HCV感染和晚期肝病患者中均获得了较高的持续病毒学应答率

Original article: Daclatasvir plus sofosbuvir with or without ribavirin achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅